CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $4.57 and traded as high as $7.45. CASI Pharmaceuticals shares last traded at $7.17, with a volume of 20,165 shares traded.
Analysts Set New Price Targets
Separately, StockNews.com started coverage on CASI Pharmaceuticals in a report on Saturday, August 3rd. They set a “hold” rating for the company.
View Our Latest Research Report on CASI
CASI Pharmaceuticals Stock Down 0.7 %
CASI Pharmaceuticals (NASDAQ:CASI – Get Free Report) last posted its quarterly earnings results on Friday, August 16th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. The business had revenue of $3.98 million during the quarter, compared to the consensus estimate of $4.43 million. CASI Pharmaceuticals had a negative return on equity of 126.20% and a negative net margin of 118.81%. As a group, sell-side analysts expect that CASI Pharmaceuticals, Inc. will post -2.56 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in CASI Pharmaceuticals stock. Howland Capital Management LLC purchased a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI – Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 40,429 shares of the biotechnology company’s stock, valued at approximately $146,000. Howland Capital Management LLC owned approximately 0.30% of CASI Pharmaceuticals as of its most recent SEC filing. 22.23% of the stock is owned by institutional investors.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.
Read More
- Five stocks we like better than CASI Pharmaceuticals
- What Is WallStreetBets and What Stocks Are They Targeting?
- Powering Your Portfolio: The Utility Sector’s Electrifying Surge
- EV Stocks and How to Profit from Them
- Adobe Stock Builds Long-Term Value: Consider Buying on the Dip
- What is Short Interest? How to Use It
- Albemarle Jumps as Lithium Stock Buying Frenzy Takes Off
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.